- Home
- NUVL vs GGAL Comparison
NUVL vs GGAL Comparison
Compare NUVL & GGAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- GGAL
- Stock Information
- Founded
- NUVL 2017
- GGAL 1905
- Country
- NUVL United States
- GGAL Argentina
- Employees
- NUVL N/A
- GGAL N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- GGAL Commercial Banks
- Sector
- NUVL Health Care
- GGAL Finance
- Exchange
- NUVL Nasdaq
- GGAL Nasdaq
- Market Cap
- NUVL 6.5B
- GGAL 5.2B
- IPO Year
- NUVL 2021
- GGAL N/A
- Fundamental
- Price
- NUVL $104.59
- GGAL $54.96
- Analyst Decision
- NUVL Strong Buy
- GGAL Buy
- Analyst Count
- NUVL 11
- GGAL 4
- Target Price
- NUVL $121.45
- GGAL $75.67
- AVG Volume (30 Days)
- NUVL 498.8K
- GGAL 4.2M
- Earning Date
- NUVL 11-10-2025
- GGAL 01-01-0001
- Dividend Yield
- NUVL N/A
- GGAL 1.28%
- EPS Growth
- NUVL N/A
- GGAL N/A
- EPS
- NUVL N/A
- GGAL 0.60
- Revenue
- NUVL N/A
- GGAL $4,565,013,669.00
- Revenue This Year
- NUVL N/A
- GGAL $9.54
- Revenue Next Year
- NUVL N/A
- GGAL $12.92
- P/E Ratio
- NUVL N/A
- GGAL $9.42
- Revenue Growth
- NUVL N/A
- GGAL N/A
- 52 Week Low
- NUVL $55.54
- GGAL $25.89
- 52 Week High
- NUVL $103.69
- GGAL $74.00
- Technical
- Relative Strength Index (RSI)
- NUVL 71.49
- GGAL 82.62
- Support Level
- NUVL $90.00
- GGAL $31.14
- Resistance Level
- NUVL $99.94
- GGAL $55.72
- Average True Range (ATR)
- NUVL 4.59
- GGAL 2.76
- MACD
- NUVL 1.10
- GGAL 2.89
- Stochastic Oscillator
- NUVL 100.00
- GGAL 96.90
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.